GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Cyclically Adjusted PB Ratio

OBI Pharma (ROCO:4174) Cyclically Adjusted PB Ratio : 1.06 (As of Jun. 30, 2025)


View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma Cyclically Adjusted PB Ratio?

As of today (2025-06-30), OBI Pharma's current share price is NT$32.70. OBI Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was NT$30.98. OBI Pharma's Cyclically Adjusted PB Ratio for today is 1.06.

The historical rank and industry rank for OBI Pharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

ROCO:4174' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.04   Med: 2.28   Max: 3.07
Current: 1.09

During the past years, OBI Pharma's highest Cyclically Adjusted PB Ratio was 3.07. The lowest was 1.04. And the median was 2.28.

ROCO:4174's Cyclically Adjusted PB Ratio is ranked better than
57.71% of 681 companies
in the Biotechnology industry
Industry Median: 1.5 vs ROCO:4174: 1.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

OBI Pharma's adjusted book value per share data for the three months ended in Mar. 2025 was NT$12.573. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$30.98 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


OBI Pharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for OBI Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma Cyclically Adjusted PB Ratio Chart

OBI Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.29 2.20 1.85

OBI Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.97 1.91 2.39 1.85 1.89

Competitive Comparison of OBI Pharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, OBI Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OBI Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where OBI Pharma's Cyclically Adjusted PB Ratio falls into.


;
;

OBI Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

OBI Pharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=32.70/30.98
=1.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OBI Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, OBI Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=12.573/134.9266*134.9266
=12.573

Current CPI (Mar. 2025) = 134.9266.

OBI Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201506 42.221 100.684 56.580
201509 42.037 100.392 56.498
201512 41.045 99.792 55.496
201603 37.698 100.470 50.626
201606 37.734 101.688 50.068
201609 36.231 101.861 47.992
201612 35.246 101.863 46.687
201703 33.015 102.862 43.306
201706 31.987 103.349 41.760
201709 30.460 104.136 39.466
201712 28.959 104.011 37.567
201803 28.981 105.290 37.139
201806 28.693 106.317 36.414
201809 26.620 106.507 33.723
201812 24.490 105.998 31.174
201903 23.544 107.251 29.620
201906 30.951 108.070 38.643
201909 29.235 108.329 36.413
201912 29.071 108.420 36.178
202003 25.154 108.902 31.165
202006 23.601 108.767 29.277
202009 21.700 109.815 26.662
202012 20.926 109.897 25.692
202103 19.967 111.754 24.107
202106 17.670 114.631 20.798
202109 16.093 115.734 18.762
202112 13.435 117.630 15.411
202203 24.379 121.301 27.117
202206 22.956 125.017 24.776
202209 22.413 125.227 24.149
202212 20.128 125.222 21.688
202303 19.253 127.348 20.399
202306 21.152 128.729 22.170
202309 18.761 129.860 19.493
202312 16.507 129.419 17.209
202403 14.299 131.776 14.641
202406 12.449 132.554 12.672
202409 10.236 133.029 10.382
202412 14.506 133.157 14.699
202503 12.573 134.927 12.573

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OBI Pharma  (ROCO:4174) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


OBI Pharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of OBI Pharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OBI Pharma Business Description

Industry
Traded in Other Exchanges
N/A
Address
Zhongxiao E Road, 6th Floor, No. 508, Section 7, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is engaged in new drugs research of novel cancer therapeutic agents for patients with unmet medical needs. The company has four reportable segments, which are anti-cancer new drug segment, bispecific monoclonal antibody new drug segment, botulinum toxin new drug segment and CDMO segment.

OBI Pharma Headlines

No Headlines